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Abstract 
Background and Purpose: Antithombotics are the mainstay of treatment in primary and secondary 
prevention of stroke and their use prior to an acute event may be associated with better outcomes.  
Methods and Results: Using data from Get With The Guidelines-Stroke with over half a million acute 
ischemic strokes recorded between Oct 2011 and Mar 2014 (n=540,993) from 1661 hospitals across the 
US, we examined the unadjusted and adjusted associations between prior antithrombotic use and clinical 
outcomes. There were 250,104 (46%) stroke patients not receiving any antithrombotic prior to stroke; of 
whom approximately a third had a documented prior vascular indication. After controlling for clinical and 
hospital factors, patients who were receiving antithrombotics prior to stroke had better outcomes 
compared with those who did not, regardless of whether a prior vascular indication was present or not: 
adjusted odds ratio (OR) (95% confidence intervals [CI]) were 0.82 (0.80-0.84) for in-hospital mortality, 
1.18 (1.16-1.19) for home as the discharge destination, 1.15 (1.13-1.16) for independent ambulatory status 
at discharge, and 1.15 (1.12-1.17) for discharge mRS of 0 or 1.  
Conclusion: Prior antithrombotic therapy was independently associated with improved clinical outcomes 
after acute ischemic stroke. Ensuring use of antithrombotics in appropriate patient populations may be 
associated with benefits beyond stroke prevention.   
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Introduction 
 
Even though use of antithrombotic medications for primary and secondary prevention of cardiovascular 
disease is increasing, many patients with indications are still not receiving antithrombotic medications and 
suffer an acute ischemic stroke [1]. It also remains unclear if prior therapy can also improve outcomes 
from those still having an acute ischemic stroke.  Possible mechanisms for such a benefit include: 
attenuating the volume of the initial thrombus, preventing clot propagation, and reducing the risk of early 
recurrent thrombosis or embolism.  
 
Despite theoretical mechanisms for benefit, existing evidence on the topic is conflicting. Kwok and 
colleagues found that prior antithrombotic use was not associated with reduced mortality up to one year 
after stroke presentation [2]. In contrast, a large registry from Canada reported a beneficial association 
between prior use of antithrombotics and improved functional outcome [3][4]. Indeed, recent studies 
found a reduction in initial stroke severity in previous antiplatelet users in ischemic stroke [5][6], 
suggesting prior antithrombotic therapy may moderate ischemic stroke evolution from the earliest 
moments of onset.  To date, however, all these studies were small or moderate in size and some of these 
conflicts may be due to unstable estimates.    
 
Using data from the American Heart Association/American Stroke Association (AHA/ASA) Get with the 
Guidelines-Stroke (GWTG-Stroke) database, our study aims were to: (1) describe characteristics of 
ischemic stroke patients by receipt or non-receipt of antithrombotic medication prior to stroke; (2) 
determine whether pre-stroke antithrombotic use is related to outcomes at discharge, and whether this 
relationship varies with indication for antithrombotic use; and (3) determine whether prior warfarin use is 
associated with outcomes at discharge among patients with atrial fibrillation (AF) or flutter, taking INR 
control into account.   
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Methods 
The AHA/ASA GWTG-Stroke database data collection methods have been previously described 
[7][8][9][10]. In brief, 1661 hospitals used an Internet-based “Patient Management Tool” (Quintiles, 
Cambridge, MA) to enter data, receive decision support, and obtain feedback via on demand reports of 
performance on quality measures and recorded data from consecutive admissions for acute ischemic 
stroke. There were a total of 624,883 patients with ischemic stroke at 1,705 participating centres between 
1st October 2011 and 31st March 2014. Of them 19,381 were transferred to another acute facility, left 
against medical advice, or had no data on discharge status; 63,738 had missing data on prior 
antithrombotic use, and further 771 patients were excluded due to data on vascular indication for use of 
antithrombotics was missing.   
 
Trained hospital personnel abstracted data using the Internet-based Patient Management Tool with 
standardized data definitions and detailed coding instructions. The Internet-based system performs checks 
to ensure that the reported data are complete and internally consistent. In addition, data quality is 
monitored for both completeness and accuracy. Hospitals that participate must receive approval through 
their local institutional review boards or a waiver of individual consent under the common rule. Quintiles 
(Cambridge, MA) is the data collection coordination centre for the American Heart Association/American 
Stroke Association Get With the Guidelines programs. The Duke Clinical Research Institute (Durham, 
NC) serves as the data analysis centre. Hospital characteristics (i.e. academic teaching status, bed size) 
were based on American Hospital Association data [10]. Past medical history was defined on the basis of 
pre-existing conditions, with the exclusion of conditions that were newly diagnosed during the hospital 
stay.  
Prior antithrombotic use was defined as any anticoagulant or antiplatelet use before the index stroke. 
Patients were considered to have a vascular indication for antithrombotic use if their medical history 
included coronary artery disease (CAD), previous stroke or transient ischemic attack (TIA), or atrial 
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fibrillation or flutter. Our study examined patient-relevant outcomes of in-hospital mortality, discharge to 
home, ability to ambulate independently at discharge, disability at the time of discharged defined using 
modified Rankin scale (mRS ≥2) and acute hospital length of stay (LOS). 
 
Statistical analysis 
Analyses were carried out using SAS version 9.3 or higher (SAS Institute, Cary NC). We compared the 
baseline characteristics for patients by (a) prior use of antithrombotic (yes vs. no) and (b) prior use of 
antithrombotic (yes vs. no) and indication (any vs. none) (4 groups). Differences are compared with 
Pearson chi-square tests for categorical and Wilcoxon rank-sum and Kruskal-Wallis tests for continuous 
variables and data are presented descriptively.   
 
To evaluate associations, multivariable logistic regression was used for binary outcomes.  Multiple 
regression was used for LOS, which was transformed using the natural log to achieve approximate 
normality. In addition to the term for prior antithrombotic use, each model also contained a term for 
antithrombotic indication, and a term for the interaction between them. Models were adjusted for 
covariates at admission including age, sex, race, BMI, medical history, on-hours arrival, and site 
characteristics.  Missing values of covariates were imputed using multiple imputation (25 imputations).  
Generalized estimating equations (GEEs) were used to account for clustering within hospitals.  
 
We present prior antithrombotic odds ratios within indication subgroups if the interaction between 
antithrombotic use and indication is significant and if not, present separate antithrombotic and indication 
odds ratios (i.e., main effects). For LOS outcome the interaction between prior antithrombotic use and 
indication was significant, and thus the ratio of expected LOS for the two groups is reported i.e. the data 
are presented as the ratio of expected LOS in the first group compared to the second, that is, (expected 
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days in group 1)/ (expected days in group 2).  Therefore, for LOS outcome, risk relationships are shown 
for each variable within levels of the other variable.  
  
Because NIHSS is missing in a proportion of patients (23%) a sensitivity analysis was performed in 
which these models were repeated, including NIHSS as a covariate, in the subset of patients with 
available NIHSS data.   
 
Persistent or paroxysmal AF/flutter during the index admission and previous medical history of AF/flutter 
were used to define AF/flutter in this study. To determine whether prior warfarin use is associated with 
outcomes among patients with AF/flutter, taking INR control into account, patients were grouped as (1) 
prior use of anticoagulants with INR > 1.4 at admission, (2) prior use of anticoagulants with INR ≤ 1.4 at 
admission, and (3) no anticoagulants prior to admission.  Patients who were on an anticoagulant but who 
do not have INR data were excluded from this analysis. Models used were the same as for the main 
analysis, except that the three warfarin groups were included in the model in place of the antithrombotic 
and indication terms, an additional term was added for non-anticoagulant antithrombotics (e.g., aspirin 
and other antiplatelet drugs), and patients taking new oral anticoagulants (NOACs) were excluded. Each 
warfarin group was compared to the no-warfarin group (reference group). 
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Results 
 
A total of 540,993 patients at 1,661 sites admitted with an ischemic stroke during the study period were 
included in the current study. Over half (53.8%) were receiving an antithrombotic agent (either an 
antiplatelet/combination or an anticoagulant); 253,552 (46.9%) on were taking antiplatelet drugs and 
57,543 (10.6%) were taking an anticoagulant (the sum total is greater than 53.8% because some patients 
were taking both) (see Supplementary Figure for inclusion and exclusion).  
 
The characteristics of all patients included in the analyses and then separately for those who received 
antithrombotics prior to the index ischemic stroke and those who did not were shown in Table 1. With 
large numbers the p values are highly significant between the two populations. People who did not take 
any antithrombotic prior to stroke were younger, more likely to be female, less likely to be Caucasian, 
more likely to have abnormal lipid profile, more likely to be a current smoker, but with lower prevalence 
of co-morbid medical conditions including previous history of stroke and AF/flutter, and were more likely 
to be ambulatory independently prior to stroke. Although many of the acute biochemistry and 
haematological parameters, and site characteristics, were statistically significantly different between these 
groups, the magnitudes of differences were negligible.  
 
Sample characteristics comparison by prior antithrombotic use and indication for its use shows pre-stroke 
antithrombotic users were older and more likely to be white. Patients without pre-stroke antithrombotic 
use despite an indication show similar characteristics to users who did not have previous cardiovascular 
diseases. The total number of the subgroups analysed by the presence or absence of prior indications for 
antithrombotic use and exclusions are presented in the Figure 1.  Approximately 30% of patients had 
mismatch between vascular indication and usage in this cohort.  Supplementary Table I shows the types 
of antithrombotic use among the users of antithrombotics before the index stroke.  
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Table 2 shows the regression model results (adjusted for variables described as in Methods), respectively, 
by prior antithrombotic use and indication. Although crude rates show poor outcome in those with prior 
use, regression models (with full adjustment) demonstrate that patients taking an antithrombotic prior to 
the index stroke were less likely to die during the hospitalization and more likely to be discharged to 
home, able to ambulate independently, and better functional outcomes at discharge compared with 
patients who were not on an antithrombotic. Supplementary Table II shows that patients with a vascular 
indication for antithrombotic use (medical history of CAD, previous stroke or TIA, or atrial fibrillation or 
flutter) were more likely to have unfavourable/negative outcomes than patients without an indication. 
There were no significant interactions between antithrombotic use and prior indication for use, indicating 
that the lower rate of in-hospital death with antithrombotic use was similar for patients with and without a 
vascular indication for use. Discharge outcome to home among patients discharged alive, and ambulatory 
status among patients able to ambulate independently prior to the event, showed results which were 
consistent with the models in the larger set of patients.  
 
Length of stay outcome analysis shows patients taking an antithrombotic prior to stroke had a shorter 
expected hospital stay than patients not on an antithrombotic prior to the event. The significant interaction 
indicates that the expected relative length of stay depends on whether or not the patient had an indication 
— there is more of an associated reduction in LOS, with antithrombotic compared to without, where there 
is an indication (see Table 2).  
 
Supplementary Tables III & IV show the results in a subset of patients in whom NIHSS was available 
with additional adjustment for NIHSS score. Results are generally consistent with those in the full cohort, 
except for LOS, which here does not have a significant interaction between antithrombotic and the 
presence or absence of an indication for its use.  
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Of 118,635 (22.1%) identified as AF/flutter, 29,425/118,636 (24.8%) had no previous medical history of 
AF/flutter but had either persistent or paroxysmal AF/flutter during the index admission (Supplementary 
Table V).  Table 3 demonstrates that patients on warfarin with INR>1.4 had better outcomes than 
patients not on warfarin.  Patients on warfarin with INR ≤ 1.4 had a higher risk of in-hospital death, lower 
likelihood of being discharged home, and a longer length of hospital stay, compared to patients not on 
warfarin prior to stroke, but a similar probability of being able to ambulate independently and having a 
low mRS score at the time of discharge.  
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Discussion 
 
To the best of our knowledge, this study is the largest to examine the association between prior 
antithrombotic use and important and relevant outcomes in patients admitted with an acute ischemic 
stroke. We found that the prior use of antithrombotics was associated with a favourable outcome for all 
outcomes assessed highlighting an important point that antithrombotics not only have effect on vascular 
outcome but also may reduce the severity of vascular outcomes.  Associations between prior 
antithrombotic medication use and better post-stroke outcomes were seen across patient subgroups. No 
significant interaction between antithrombotic use and indication was observed except for LOS outcome.  
 
To date, the literature around the impact of prior antithrombotic use on stroke outcome has been 
inconsistent and shown conflicting results. However, they were limited by relatively small sample size 
(Sanosian et al, n=260) [11] (Vibo et al, n=433) [12], or focused on mortality alone [2][12], or in a 
particular patient population or of certain age [13], or examined the stroke severity only [14]. Relatively 
larger studies again showed conflicting results [2][3][4][5][6][15]. The key advantages of our study are 
much larger sample size and analysis of diverse relevant and important outcomes for patients. 
 
These findings may have important clinical implications. It appears that in US setting, a substantial 
proportion of patients who sustained ischemic stroke (78,465/540,993=14.5%) would have potentially 
benefited from antithrombotic use as a secondary preventive measure were not receiving antithrombotic 
agents at the time of index stroke onset. Similarly, we found antithrombotic use prior to stroke without a 
documented vascular indication in a substantial proportion of patients (Supplementary Table 2). This use 
may be due to other appropriate indications but could also reflect self-medication, which would be 
concerning due to the potential harm from drug side effects. 
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White et al [1] highlighted similar mismatches and the fact whilst half of strokes cases were on 
antithrombotics and yet developed stroke, half of stroke patients might have been identified as high risk 
and been prescribed an antithrombotic medication that would have prevented a substantial number of 
stroke events. This, in combination with our current study findings, further strengthens the argument to 
base antithrombotic medication use on improved risk prediction scores. Indeed, Loke et al [16] recently 
highlighted the lack of sensitivity of existing cardiovascular risk prediction tools in reliably identifying 
those groups of patients who are most likely to subsequently develop cardiovascular (CV) adverse events 
[17]. Most recent guidelines from US [18], Europe [19], UK [20] and ATP III [21] mainly focused on CV 
risk factors and use of antiplatelets in primary prevention was less well focused perhaps due to presumed 
adherence to established guidance.   
 
The strengths of our study include the large sample size and prospective data collection. One of the key 
strengths of the paper includes the robust statistical analysis with ability to control for potential 
confounders as well as ability to understand the confounding effect by indication through analysis of 
indication for antithrombotic vs. their effect on the outcomes examined. We were able to examine the 
outcomes by prior antithrombotic use as well as by vascular indication. We were also able to examine the 
outcomes by prior warfarin use and INR among patients with AF/flutter. Further, we were able to analyse 
the data taken into account of the stroke severity at onset (e.g., National Institutes of Health Stroke Scale 
(NIHSS) score) in this current report.  
 
Our study has some limitations. As a hospital-based registry some cases of stroke might not have been 
included, such as patients who died before admission. Patients and hospitals may not be entirely 
representative of the U.S population but the sample population is comparable to all US patients 
hospitalized with stroke [22]. Residual measured and unmeasured confounders may account for some of 
these findings such as factors that could have influenced prior use of antithrombotic therapy and 
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adherence to prescribed therapy. For example, those who use antithrombotic agents may have a ‘healthy 
user’ effect or greater use of health care. Whilst a substantial proportion of patients had missing data on 
NIHSS and that was due to non-random missing, repeating the analyses in those who had NIHSS data 
yielded the similar results. As an observational study the causality cannot be assumed. Nonetheless, the 
observed associations have plausible explanations, as we alluded to in the introduction. 
 
In summary, using the AHA/ASA GWTG-Stroke registry data with over half a million of ischemic stroke 
patients, we present evidence that prior antithrombotic use was associated with favorable outcomes in 
ischemic stroke and thus highlights the importance of primary and secondary stroke prevention with 
antithrombotic medications when indicated. A substantial proportion of patients in our study sustained 
stroke despite being on antithrombotic agents and the fact that patients with INR <1.4 among people with 
AF/flutter had worse outcomes suggests the urgent need to address issues of medication compliance, and 
adequate anticoagulation in stroke prevention. Ensuring appropriate use of antithrombotics at a population 
level may have substantial benefit to patients with stroke and health economy in a global scale. 
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Table 1: Baseline Patients Descriptive Statistics by Prior Antithrombotic Use 
 
Variable Overall 
(N=540,993) 
Prior antithrombotic 
(N=290,889) 
No prior antithrombotic 
(N=250,104) 
P-value 
Demographics        
        
Age (years), median (IQR) 72 (61-82)  75 (65-84)  67 (56-80) <0.0001 
        
Female Sex, n (%)  276687 (51.18)  148179 (50.97)  128508 (51.41) 0.001 
        
Race, n (%)       <0.0001 
White  379289 (70.23)  214862 (73.97)  164427 (65.86)  
Black   91176 (16.88)   42793 (14.73)   48383 (19.38)  
Hispanic   35268 (6.53) 16394   (5.64)   18874 (7.56)  
Asian   14338 (2.65)    6474 (2.23)    7864 (3.15)  
Other   20026 (3.71)    9930 (3.42)   10096 (4.04)  
        
Presentation        
        
On-hour arrival (M-F 7a-6p), n (%)  292989 (54.16)  158233 (54.40)  134756 (53.88) 0.0001 
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Variable Overall 
(N=540,993) 
Prior antithrombotic 
(N=290,889) 
No prior antithrombotic 
(N=250,104) 
P-value 
NIH Stroke Scale, median (IQR)  4 (1-10) 4 (1-10) 4  (1-9) <0.0001 
N (% missing)  415034 (23.3)    223243 (23.3)   191791 (23.3)  
        
Systolic BP (mmHg), median (IQR) 155 (136-177) 153 (135-174) 156 (137-179) <0.0001 
N (% missing)  427326 (21.0)  229521 (21.1)  197805 (20.9)  
        
Heart rate (per min), median (IQR) 79 (68-91) 78 (68-89) 80 (70-93) <0.0001 
N (% missing)  420998 (22.2)   226011 (22.3)  194987 (22.0)  
        
BMI (kg/m2), median (IQR) 27.2 (23.7-31.6)  27.2 (23.7-31.5) 27.1 (23.6-31.6) 0.004 
N (% missing)  389151 (28.1)   209930 (27.8)   179221 (28.3)   
        
Lab results        
        
Serum creatinine (mg/dL), median (IQR) 1.0   (0.8-1.3) 1.0   (0.8-1.3) 1.0 (0.8-1.2) <0.0001 
N (% missing)  424629  (21.5)   228171  (21.6)   196458 (21.5)  
        
Total cholesterol (mg/dL), median (IQR) 165 (137-198) 156 (130-188) 175 (147-207) <0.0001 
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Variable Overall 
(N=540,993) 
Prior antithrombotic 
(N=290,889) 
No prior antithrombotic 
(N=250,104) 
P-value 
N (% missing)  393327 (27.3)  207828 (28.6)  185499 (25.8)  
        
HDL (mg/dL), median (IQR) 42  (34 -52 ) 41  (34 -51 ) 42  (34 -53 ) <0.0001 
N (% missing)  387763 (28.3)   204917 (29.6)   182846 (26.9)  
        
LDL (mg/dL), median (IQR) 95  (72 -123 ) 88  (67 -114 ) 104  (80 -132 ) <0.0001 
N (% missing)  470591 (13.0)   248304 (14.6)   222287 (11.1)  
        
Triglycerides (mg/dL), median (IQR)  111  (79 -161 ) 109  (78 -159 ) 113  (80 -164 ) <0.0001 
N (% missing)  389988 (27.9)  205899 (29.2)  184089 (26.4)  
        
Glucose (mg/dL), median (IQR)  119  (101 -156 ) 120  (101 -158 ) 117  (100 -153 ) <0.0001 
N (% missing)  418499 (22.6)  224843 (22.7)  193656 (22.6)  
        
Medical History, n (%)        
        
Hypertension  414163 (76.56)  241323 (82.96)  172840 (69.11) <0.0001 
        
22 
 
Variable Overall 
(N=540,993) 
Prior antithrombotic 
(N=290,889) 
No prior antithrombotic 
(N=250,104) 
P-value 
Diabetes mellitus  181960 (33.63)  112281 (38.60)   69679 (27.86) <0.0001 
        
CAD/prior MI  136054 (25.15)  104966 (36.08)   31088 (12.43) <0.0001 
        
Smoker   98326 (18.18)   41038 (14.11)   57288 (22.91) <0.0001 
        
Prosthetic heart valve    7179 (1.33)    6059 (2.08)    1120 (0.45) <0.0001 
        
CHF   49611 (9.17)   36665 (12.60)   12946 (5.18) <0.0001 
        
PVD   25807 (4.77)   19700 (6.77)    6107 (2.44) <0.0001 
        
Prior stroke  137221 (25.36)  101765 (34.98)   35456 (14.18) <0.0001 
        
Atrial fib/flutter  101520 (18.77)   78077 (26.84)   23443 (9.37) <0.0001 
        
Carotid stenosis   19915 (3.68)   15930 (5.48)    3985 (1.59) <0.0001 
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Variable Overall 
(N=540,993) 
Prior antithrombotic 
(N=290,889) 
No prior antithrombotic 
(N=250,104) 
P-value 
Ambulatory status prior to index stroke       <0.0001 
Independent with or without a device  388622 (84.09)  203870 (81.93)  184752 (86.61)  
Needs assistance from another person   26327 (5.70)   17194 (6.91)    9133 (4.28)  
Unable to ambulate   17752 (3.84)   11172 (4.49)    6580 (3.08)  
Missing (%) 21.0   21.1   20.7    
        
Antithrombotics at admission, n (%)        
        
Antiplatelet    253552 (87.34)    
        
Anticoagulant     57543 (19.82)    
        
Type unspecified       574 (0.20)    
        
INR (patients on warfarin), median (IQR)   1.69 (1.22-2.30)    
N   21743     
Missing (%)   23.7     
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Variable Overall 
(N=540,993) 
Prior antithrombotic 
(N=290,889) 
No prior antithrombotic 
(N=250,104) 
P-value 
Hospital characteristics        
        
Teaching hospital, n (%)  322708 (60.72)  172461 (60.41)  150247 (61.07) <0.0001 
        
Number of beds, median (IQR)  327 (252-567) 370 (250-561) 374 (255-569) <0.0001 
        
Annual ischemic stroke admissions, median (IQR)  213 (145-333) 214 (145-333) 213 (144-333) 0.41 
        
Annual volume of IV t-PAs, median (IQR) 15.5 (8.8-25.4) 15.4 (8.7-25.3) 15.6 (8.8-26.0) <0.0001 
        
Geographic region, n (%)       <0.0001 
West  100506 (18.58)   52650 (18.10)   47856 (19.13)  
South  193037 (35.68)  100423 (34.52)   92614 (37.03)  
Midwest  107701 (19.91)   61039 (20.98)   46662 (18.66)  
Northeast  139749 (25.83)   76777 (26.39)   62972 (25.18)  
        
Rural location, n (%)   26767 (4.99)   15570 (5.39)   11197 (4.51) <0.0001 
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Abbreviations: IQR = inter quartile range; CAD = coronary artery disease; CHF = chronic heart failure; MI = myocardial infarction; PVD = peripheral 
vascular disease; BP= blood pressure; BMI = body mass index; INR = international normalized ratio; HDL = high density lipoprotein; LDL = low density 
lipoprotein 
Data for each variable are missing in <5% of patients unless noted. Percentages are calculated using only non-missing values. 
P-values for categorical variables are from Pearson chi-square tests, and for continuous variables are from Wilcoxon rank sum tests.
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Table 2: Outcomes by prior antithrombotic use and indication 
 
Interaction 
between anti-
thrombotic use 
and indication 
Prior antithrombotic use 
 vs. no prior use 
Indication for antithrombotic use  
vs. no indication 
Outcome P OR (95%CI) P OR (95% CI) P 
In-hospital death 0.29 0.82 (0.80, 0.84) <0.0001 1.49 (1.45, 1.54) <0.0001 
Discharge to home 0.33 1.18 (1.16, 1.19) <0.0001 0.72 (0.71, 0.72) <0.0001 
–where discharged alive 0.55 1.16 (1.15, 1.18) <0.0001 0.73 (0.72, 0.74) <0.0001 
Able to ambulate independently at discharge 0.43 1.15 (1.13, 1.16) <0.0001 0.70 (0.69, 0.71) <0.0001 
–where able to ambulate independently 
prior to index stroke 
0.61 1.17 (1.15, 1.19) <0.0001 0.77 (0.76, 0.78) <0.0001 
mRS = 0 or 1 at discharge 0.55 1.15 (1.12, 1.17) <0.0001 0.66 (0.65, 0.67) <0.0001 
Length of Stay    
 
Interaction between 
anti-thrombotic use 
and indication 
Prior antithrombotic use  
vs. no prior use  
Ratio (95%CI) 
Indication for antithrombotic use  
vs. no indication  
Ratio (95%CI) 
Outcome P 
Indication for 
antithrombotic use  
No indication for 
antithrombotic use  
Prior 
antithrombotic use  
No prior 
antithrombotic use  
Length of stay 0.0049 0.95 (0.94, 0.95) 0.96 (0.95, 0.97) 1.12 (1.11, 1.12) 1.13 (1.12, 1.14) 
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Interaction between 
anti-thrombotic use 
and indication 
Prior antithrombotic use 
 vs. no prior use 
Indication for antithrombotic use  
vs. no indication 
Outcome P OR (95%CI) P OR (95% CI) P 
Length of stay (ratio) 0.0049 0.96 (0.95, 0.97) <0.0001 1.13 (1.12, 1.14) <0.0001 
For the all endpoints, there was no significant interaction between prior antithrombotic use and indication; therefore, odds ratios are shown for these two 
variables separately.Modeling for LOS:  A multiple regression model was used.  Patients were excluded if they transferred in or transferred out to acute care, 
or had an in-hospital stroke. In all other respects the LOS model is the same as for the binary endpoints. 
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Table 3: Outcomes by prior warfarin use and INR, among patients with AF/flutter 
Outcome / subgroup N Event rate 
Adjusted Odds ratio 
(95% CI) P 
All patients with AF/flutter* 121,287    
In-hospital mortality  
Prior warfarin, INR > 1.4 10,774 7.9% (853) 0.99 (0.92, 1.07) 0.79 
Prior warfarin, INR ≤ 1.4 5,255 9.2% (482) 1.19 (1.08, 1.31) 0.0005 
No warfarin 105,258 8.6% (9,060) ref  
Discharge to home  
Prior warfarin, INR > 1.4 10,774 36.6% (3,942) 1.12 (1.08, 1.18) <.0001 
Prior warfarin, INR ≤ 1.4 5,255 31.2% (1,637) 0.81 (0.76, 0.87) <.0001 
No warfarin 105,258 32.6% (34,312) ref  
Able to ambulate independently  
Prior warfarin, INR > 1.4 8,979 42.7% (3,834) 1.20 (1.15, 1.26) <.0001 
Prior warfarin, INR ≤ 1.4 4,308 38.5% (1,658) 0.96 (0.90, 1.03) 0.29 
No warfarin 78,401 37.4% (29,343) ref  
Modified Rankin Scale = 0 or 1  
Prior warfarin, INR > 1.4 5,846 20.0% (1,169) 1.09 (1.01, 1.17) 0.028 
Prior warfarin, INR ≤ 1.4 2,866 17.7% (507) 0.89 (0.80, 0.99) 0.028 
No warfarin 47,183 17.8% (8,395) ref  
Length of stay  
median 
(25th, 75th percentiles) 
Ratio  
(95% CI)  
Prior warfarin, INR > 1.4 8,947 4 (3, 6) 0.93 (0.92, 0.95) <.0001 
Prior warfarin, INR ≤ 1.4 4,294 5 (3, 8) 1.10 (1.08, 1.13) <.0001 
No warfarin 86,319 4 (3, 7) ref  
* Model covariates as described in the methods, including a model term for non-anticoagulant antithrombotic medications (e.g. aspirin). Of 130,945 with 
known or newly diagnosed atrial fibrillation or flutter during the hospital stay, 143 (0.1%) were excluded for missing antithrombotic information, 4,930 
(3.8%) were excluded for missing INR, and 4,585 (3.5%) for taking novel oral anticoagulants (NOACs). 
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Figure 1: Consort Diagram of Patient Exclusion 
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Supplementary Table I: The frequency distribution by type of prior antithrombotic agents 
Antiplatelet Percent (n) of pts on an antiplatelet 
N 167,791 
Aspirin 86.6% (145,255) 
Clopidogrel 23.1% (38,696) 
Aspirin/dipyridamole 3.1% (5,128) 
Other antiplatelet 0.4% (681) 
Prasugrel 0.1% (100) 
Ticlopodine <0.1% (67) 
Ticagrelor <0.1% (48) 
Anticoagulant Percent (n) of pts on an anticoagulant 
N 36,704 
Warfarin 77.7% (28,503) 
Dabigatran 7.8% (2,876) 
Rivaroxaban 6.6% (2,423) 
LMW heparin 6.3% (2,299) 
Other anticoagulant 1.4% (514) 
Unfractionated heparin 1.1% (416) 
Apixaban 0.5% (181) 
Fondaparinux 0.4% (133) 
Argatroban <0.1% (13) 
Desirudin <0.1% (4) 
Lepirudin <0.1% (3) 
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Supplementary Table II: Outcomes (event rates) by prior antithrombotic use and indication   
 Indication for antithrombotic use No indication for antithrombotic use 
Outcomes Prior antithrombotic use No prior use Prior antithrombotic use No prior use 
N 214,948 78,465 75,941 171,639 
In-hospital death 5.5% (11,829) 6.5% (5,121) 3.6% (2,730) 3.8% (6,538) 
Discharge destination     
 Home 43.5% (93,599) 41.4% (32,478) 53.9% (40,932) 56.7% (97,235) 
 Other health care facility* 45.1% (96,995) 45.3% (35,522) 39.1% (29,691) 36.7% (63,071) 
 Hospice 5.8% (12,525) 6.8% (5,344) 3.4% (2,588) 2.8% (4,795) 
 Died 5.5% (11,829) 6.5% (5,121) 3.6% (2,730) 3.8% (6,538) 
Ambulatory status at discharge     
 N 184,071 66,732 63,221 144,761 
 Able to ambulate 
independently 
42.5% (78,200) 40.2% (26,834) 53.5% (33,823) 56.1% (81,185) 
 Able to ambulate with 
assistance 
30.7% (56,546) 30.0% (19,988) 27.4% (17,300) 25.8% (37,369) 
 Unable to ambulate 17.5% (32,142) 19.1% (12,717) 11.9% (7,546) 10.9% (15,728) 
 Died 6.4% (11,829) 7.7% (5,121) 4.3% (2,730) 4.5% (6,538) 
 ND 2.9% (5,354) 3.1% (2,072) 2.9% (1,822) 2.7% (3,941) 
Modified Rankin Scale at 
discharge 
    
 N 95,000 35,026 32,330 75,631 
 0 10.1% (9,589) 9.4% (3,281) 15.2% (4,912) 16.7% (12,650) 
 1 14.8% (14,080) 13.9% (4,869) 19.9% (6,421) 20.9% (15,838) 
 2 9.9% (9,435) 9.2% (3,239) 11.7% (3,790) 11.6% (8,736) 
 3 14.2% (13,512) 13.9% (4,858) 13.9% (4,489) 13.5% (10,202) 
 4 27.1% (25,700) 26.7% (9,337) 23.5% (7,582) 22.1% (16,731) 
 5 12.8% (12,162) 14.0% (4,890) 8.3% (2,671) 7.4% (5,606) 
 6 11.1% (10,522) 13.0% (4,552) 7.6% (2,465) 7.8% (5,868) 
Length of stay (days)     
 N 179,908 65,737 63,074 142,686 
 Median (25th, 75th percentiles) 4 (2, 6) 4 (3, 6) 3 (2, 5) 3 (2, 6) 
 
*Skilled nursing facility, inpatient rehabilitation facility, long term care hospital, intermediate care facility, or other. 
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Supplementary Table III: Outcomes (event rates) by prior antithrombotic use and indication – among patients with NIHSS data   
 Indication for antithrombotic use No indication for antithrombotic use 
Outcomes Prior antithrombotic use No prior use Prior antithrombotic use No prior use 
N 165,339 59,512 57,904 132,279 
In-hospital death 5.2% (8,539) 5.9% (3,505) 3.2% (1,856) 3.3% (4,408) 
Discharge destination     
 Home 44.1% (72,985) 42.2% (25,108) 54.3% (31,450) 57.0% (75,394) 
 Other health care facility* 45.1% (74,531) 45.5% (27,077) 39.3% (22,742) 37.1% (49,101) 
 Hospice 5.6% (9,284) 6.4% (3,822) 3.2% (1,856) 2.6% (3,376) 
 Died 5.2% (8,539) 5.9% (3,505) 3.2% (1,856) 3.3% (4,408) 
Ambulatory status at discharge     
 N 142,333 50,855 48,859 112,394 
 Able to ambulate 
independently 
43.6% (62,075) 41.4% (21,064) 54.7% (26,719) 57.0% (64,117) 
 Able to ambulate with 
assistance 
30.5% (43,440) 30.0% (15,266) 27.1% (13,256) 25.8% (28,977) 
 Unable to ambulate 17.2% (24,454) 18.8% (9,584) 11.8% (5,764) 10.8% (12,180) 
 Died 6.0% (8,539) 6.9% (3,505) 3.8% (1,856) 3.9% (4,408) 
 ND 2.7% (3,825) 2.8% (1,436) 2.6% (1,264) 2.4% (2,712) 
Modified Rankin Scale at 
discharge 
    
 N 76,860 27,831 26,285 61,429 
 0 10.7% (8,229) 10.1% (2,801) 15.7% (4,131) 17.3% (10,628) 
 1 15.2% (11,720) 14.3% (3,988) 20.3% (5,342) 21.4% (13,130) 
 2 10.1% (7,755) 9.4% (2,604) 11.9% (3,138) 11.7% (7,193) 
 3 14.2% (10,929) 14.1% (3,928) 13.9% (3,661) 13.4% (8,248) 
 4 27.1% (20,826) 26.9% (7,479) 23.5% (6,167) 22.4% (13,746) 
 5 12.7% (9,738) 14.0% (3,889) 8.2% (2,155) 7.4% (4,527) 
 6 10.0% (7,663) 11.3% (3,142) 6.4% (1,691) 6.4% (3,957) 
Length of stay (days)     
 N 138,914 50,083 48,243 110,383 
 Median (25th, 75th percentiles) 4 (2, 6) 4 (3, 6) 3 (2, 5) 3 (2, 5) 
 
*Skilled nursing facility, inpatient rehabilitation facility, long term care hospital, intermediate care facility, or other.  
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Supplementary Table IV: Outcomes (model results) by prior antithrombotic use and indication among patients with NIHSS data 
 
 
Interaction 
between anti-
thrombotic use 
and indication 
Prior antithrombotic use 
 vs. no prior use 
Indication for antithrombotic use  
vs. no indication 
Outcome P OR (95%CI) P OR (95% CI) P 
In-hospital death 0.74 0.92 (0.89, 0.96) <0.0001 1.10 (1.06, 1.14) <0.0001 
Discharge to home 0.22 1.13 (1.11, 1.15) <0.0001 0.90 (0.88, 0.91) <0.0001 
–where discharged alive 0.16 1.12 (1.11, 1.14) <0.0001 0.91 (0.89, 0.92) <0.0001 
Able to ambulate independently at discharge 0.41 1.11 (1.09, 1.13) <0.0001 0.85 (0.83, 0.86) <0.0001 
–where able to ambulate independently 
prior to index stroke 
0.12 1.13 (1.11, 1.15) <0.0001 0.91 (0.89, 0.93) <0.0001 
mRS = 0 or 1 at discharge 0.74 1.09 (1.07, 1.12) <0.0001 0.83 (0.81, 0.85) <0.0001 
LOS (ratio) 0.31 0.97 (0.96, 0.97) <0.0001 1.07 (1.06, 1.07) <0.0001 
For the endpoints above, there was no significant interaction between prior antithrombotic use and indication; therefore, odds ratios are shown for these two 
variables separately. 
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Supplementary Table V: Sample distribution of AF/Flutter by medical history and recorded persistent 
paroxysmal AF/flutter during index admission 
 
Persistent or paroxysmal AF/Flutter  
during index admission 
 
 Yes No Unknown Total 
Medical history of 
AF/Flutter  
    
         Yes 89,210 12,001 309 101,520 
         No 29,425 408,471 1577 473,473 
Total 118,635 420,472 1866 540,993 
 
 
